Medicine and Dentistry
Endoscopy
100%
Molecular Imaging
68%
Inflammatory Bowel Disease
60%
Radioactive Tracer
47%
Esophageal Cancer
42%
Cetuximab
36%
Vedolizumab
36%
Chemoradiotherapy
36%
Target Cell
30%
Drug Distribution
30%
Gastrointestinal Tract
30%
Epidermal Growth Factor Receptor
24%
Primary Tumor
24%
Neoplasm
21%
Bevacizumab
21%
Barrett Esophagus
20%
Immunocompetent Cell
17%
White Light Endoscopy
15%
Immunohistochemistry
15%
Biological Marker
12%
Mucosa
11%
Malignant Neoplasm
11%
Narrow Band Imaging
9%
Esophagus Injury
9%
Esophageal Adenocarcinoma
9%
Receptor Expression
9%
Needle Biopsy
9%
Lymph Node
9%
Endocytoscopy
6%
Chromoendoscopy
6%
Dysplasia
6%
Confocal Laser Scanning Microscopy
6%
Optical Coherence Tomography
6%
Mucosal Surface
6%
Functional Imaging
6%
Raman Spectrometry
6%
Inflammatory Disorder
6%
Immunoglobulin Producing Cell
6%
Patient with Inflammatory Bowel Disease
6%
Immunotherapy Drug
6%
Inflammatory Bowel Disease
6%
Combination Therapy
6%
Esophagus Tumor
6%
Durvalumab
6%
Medicine
6%
Tumor Cell
6%
Fluorescence Microscopy
5%
Ex Vivo
5%
Intravenous Drug Administration
5%
Isoniazid
5%
Keyphrases
Esophageal Cancer
42%
Primary Tumor Site
30%
Neoadjuvant Chemoradiotherapy (nCRT)
30%
Response Monitoring
30%
Fluorescence Endoscopy
30%
Ultrasound-guided
30%
Quantitative Fluorescence
30%
Invisible
30%
Fluorescence Molecular Imaging
30%
Gastrointestinal Tract
30%
Healthy Tissue
24%
Bevacizumab
24%
Residual Tumor Tissue
18%
Image-enhanced Endoscopy
12%
Lymph Node
12%
Intrinsic Fluorescence
12%
Magnifying Endoscopy
12%
Ultrasound-guided Core Needle Biopsy
12%
Single Fiber
12%
Molecular Endoscopy
12%
Immune Cells
12%
Inflammatory Bowel Disease
12%
Colorectal Cancer
12%
Preclinical Application
6%
Delayed Failure
6%
Endocytoscopy
6%
Advanced Esophageal Cancer
6%
Tissue Optical Properties
6%
Reduced Scattering Coefficient
6%
Treatment Response
6%
Ratio Values
6%
Target-to-background Ratio
6%
Before Surgery
6%
Endoscopic Surgery
6%
Tracer Dose
6%
Metastasis
6%
Active Surveillance
6%
Fluorescent Tracer
6%
Inflammatory Diseases
6%
Chemotherapy
6%
Molecular Biomarkers
6%
Inflamed Tissue
6%
Innovative Technique
6%
Cetuximab
6%
Technical Development
6%
Personalized Treatment
6%
Tumor
6%
Tumor Cells
6%
Fluorescently Labeled
6%
Cancer Disease
6%
Pharmacology, Toxicology and Pharmaceutical Science
Tracer
54%
Inflammatory Bowel Disease
50%
Esophagus Cancer
50%
Neoplasm
42%
Vedolizumab
39%
Cetuximab
39%
Chemoradiation Therapy
39%
Drug Distribution
30%
Epidermal Growth Factor Receptor
30%
Primary Tumor
30%
Bevacizumab
27%
Barrett Esophagus
24%
Malignant Neoplasm
15%
Esophageal Adenocarcinoma
12%
Esophagus Injury
12%
Biological Marker
9%
Inflammatory Disease
9%
Esophagus Tumor
9%
Combination Therapy
9%
Immunotherapy Drug
9%
Chemotherapy
9%
Durvalumab
9%
Isoniazid
6%
Fluorescence Microscopy
5%
